CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 48 enrolled
Drug / intervention
Convalescent Plasmabiological
Likely dose
Convalescent Plasma 2 Unitsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04343261
NCT04343261Phase 2Completed
CompareCT.gov

Convalescent Plasma in the Treatment of COVID 19

Trinity Health Of New England·interventional·Posted Apr 13, 2020·Updated Sep 24, 2020

In Brief

A Phase 2 clinical trial evaluating Convalescent Plasma for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and 2 related conditions. Completed, enrolled 48 participants across 1 site.

Detailed Summary

The purpose of this study is to collect blood from previously COVID-19 infected persons who have recovered and use it as a treatment for those who are currently sick with a severe or life-threatening COVID-19 infection.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSevere Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), COVID, Coronavirus
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
202120222023202420252026
First PostedApr 13, 2020
Enrollment StartApr 10, 2020
Primary CompletionJul 23, 2020
Study CompletionAug 13, 2020
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 6.2 years ago

Interventions

Convalescent Plasmabiological

treatment with 2 Units of convalescent plasma